AVEO PHARMACEUTICALS INC (AVEO) Stock Price & Overview
NASDAQ:AVEO • US0535883070
The current stock price of AVEO is 15 USD. Today AVEO is down by 0%. In the past month the price increased by 0.6%. In the past year, price increased by 338.6%.
AVEO Key Statistics
- Market Cap
- 521.447M
- P/E
- N/A
- Fwd P/E
- 27.40
- EPS (TTM)
- -0.84
- Dividend Yield
- N/A
AVEO Stock Performance
AVEO Stock Chart
AVEO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to AVEO. When comparing the yearly performance of all stocks, AVEO is one of the better performing stocks in the market, outperforming 99.55% of all stocks.
AVEO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVEO. AVEO has a bad profitability rating. Also its financial health evaluation is rather negative.
AVEO Earnings
AVEO Forecast & Estimates
10 analysts have analysed AVEO and the average price target is 15.3 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 15.
For the next year, analysts expect an EPS growth of 59.87% and a revenue growth 163.12% for AVEO
AVEO Groups
Sector & Classification
AVEO Financial Highlights
Over the last trailing twelve months AVEO reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 56.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.94 |
AVEO Ownership
AVEO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.19 | 402.577B | ||
| AMGN | AMGEN INC | 16.11 | 203.574B | ||
| GILD | GILEAD SCIENCES INC | 16.43 | 181.247B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.66 | 125.079B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 81.897B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.52 | 42.495B | ||
| INSM | INSMED INC | N/A | 30.048B | ||
| BIIB | BIOGEN INC | 11.5 | 27.955B | ||
| NTRA | NATERA INC | N/A | 27.865B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.84 | 23.875B | ||
| MRNA | MODERNA INC | N/A | 22.105B | ||
| EXAS | EXACT SCIENCES CORP | 339.75 | 19.738B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.736B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AVEO
Company Profile
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2010-03-12. The firm is focused on delivering medicines for patients with cancer. The Company’s commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The firm markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. The company also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company’s pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).
Company Info
IPO: 2010-03-12
AVEO PHARMACEUTICALS INC
30 Winter Street
Boston MASSACHUSETTS 02108 US
CEO: Michael Bailey
Employees: 114
Phone: 18574000101.0
AVEO PHARMACEUTICALS INC / AVEO FAQ
What does AVEO do?
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2010-03-12. The firm is focused on delivering medicines for patients with cancer. The Company’s commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The firm markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. The company also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company’s pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).
What is the current price of AVEO stock?
The current stock price of AVEO is 15 USD.
Does AVEO PHARMACEUTICALS INC pay dividends?
AVEO does not pay a dividend.
What is the ChartMill rating of AVEO PHARMACEUTICALS INC stock?
AVEO has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about AVEO PHARMACEUTICALS INC (AVEO) stock?
10 analysts have analysed AVEO and the average price target is 15.3 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 15.
How many employees does AVEO PHARMACEUTICALS INC have?
AVEO PHARMACEUTICALS INC (AVEO) currently has 114 employees.